Uniting Our Strengths for Advanced Healthcare Solutions

Airblend AG Expands Product Portfolio and Production Capacity to Deliver Advanced Healthcare Solutions Globally through a strategic transaction with Elmaslar Medikal.

Steinhausen, Switzerland, [November 5, 2024] — Airblend AG, a leading global medical technology company specializing in High-Flow Nasal Oxygen (HFNO) respiratory therapy devices, is pleased to announce a significant expansion of its product portfolio and production capacity. Through a strategic merger and acquisition process, Airblend aims to enhance healthcare solutions worldwide by uniting its innovative capacity and attention to detail with Elmaslar Medikal’s extensive product line.

Airblend, known for enabling high-flow therapy to millions, is expanding its product line to include a comprehensive range of medical devices. The new additions encompass surgical aspirators, nebulizers, oxygen concentrators, and rescue products such as cervical collars, tourniquets, and first aid kits. This expansion allows Airblend to offer a broader spectrum of advanced healthcare solutions to patients and healthcare providers globally.

Leveraging Combined Expertise for Global Health
"Our commitment to innovation and meticulous attention to detail, combined with Elmaslar’s extensive product experience and production capacity, forms the cornerstone of this strategic expansion," said Cem Vardar, CEO of Airblend AG. "By uniting our strengths with those of Elmaslar Medikal, we are uniquely positioned to deliver advanced healthcare solutions globally, ensuring quality while optimizing costs through enhanced production capabilities."
Joining the Airblend AG board, Alper Sahin, CEO of Elmaslar Medikal, commented: "We are excited to become part of Airblend's vision to improve people's lives worldwide. Our shared values and combined expertise will enable us to provide high-quality medical devices to even more patients and healthcare professionals. Together, we will continue to innovate and expand our reach, building on our experience in over 70 countries."

Future Roadmap and Enhanced Commitment
Looking ahead, Airblend will focus on developing new models of the products now integrated into its portfolio, leveraging the combined expertise to introduce innovative solutions that meet evolving healthcare needs. The company is also enhancing its commitment to producing its key products in Switzerland, ensuring that the hallmark of precision and quality continues to define its offerings.
Furthermore, Airblend is exploring opportunities to enter new markets and considering the establishment of additional production facilities. This strategic expansion aims to better serve healthcare providers and patients worldwide, aligning with Airblend's mission to improve people's lives on a global scale.

About Airblend AG
Airblend AG is a global medical technology company specializing in fluid dynamics. The company's exceptional engineering team designs innovative medical devices that enhance patient care and improve healthcare outcomes. Leveraging its strong global market entry experience and robust network of international partners, Airblend effectively expands its market share and delivers high-quality solutions to healthcare providers and patients worldwide. Committed to excellence and innovation, Airblend is dedicated to advancing medical technology to make a meaningful impact on global health.

About Elmaslar Medikal
Elmaslar JSC, established in 2006, manufactures surgical aspirators, oxygen concentrators, ultrasonic nebulizers, compressor nebulizers, and rescue solutions. Operating under the motto "Life starts with health, it continues with your loved ones," Elmaslar exports to 70 countries and continues to serve with new projects.

For more information, visit www.airblendmedical.com.